[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcoidosis-pulmonary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcoidosis-pulmonary":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,72,98,124,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643962","phase-2-evaluation-of-the-efficacy-and-safety-of-compound-betamethasone-in-pulmonary-sarcoidosis-100643962",false,"NCT07668895","Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed within the past 3 months with stage I-II (based on chest CT) treatment-naive pulmonary sarcoidosis, meeting the following: A. Histopathological diagnosis of sarcoidosis via tissue biopsy (bronchial mucosa, intrathoracic lymph nodes, lung, pleura, etc.) obtained during bronchoscopy; B. Chest HRCT showing mediastinal and hilar lymphadenopathy, with or without pulmonary infiltrates (nodules, patchy opacities, ground-glass opacities, etc.); C. CT stage confirmed independently by at least two experts in the field (among three experts reviewing the chest HRCT images).\n* Requiring systemic glucocorticoid therapy.\n* Able to complete scheduled follow-up visits.\n* Patient and family members understand the study protocol, are willing to participate in this study, and are able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent.\n* Subjects who cannot comply with the follow-up schedule as required by the protocol.\n* Presence of other serious diseases that, in the investigator's judgment, may affect patient safety or compliance.\n* Any significant clinical or laboratory abnormalities that, in the investigator's judgment, may affect safety evaluation.\n* Pregnant or breastfeeding women, or patients who cannot use effective contraception during the study period and within 3 months after the study ends.\n* Active malignancy requiring treatment (surgery, medical therapy, or radiotherapy).\n* Hypersensitivity to Diprospan (Compound Betamethasone) or prednisone.","ALL","18 Years","100 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II). It will also learn about its safety compared to the standard treatment, prednisone.\n\nThe main questions it aims to answer are:\n\n* How much does the study drug improve lung function (measured by a test called FVC%) after 24 weeks of treatment?\n* How does it compare to prednisone in controlling symptoms, reducing chest lymph node swelling, and preventing relapse? Researchers will compare Compound Betamethasone injections (given once every 4 weeks) to prednisone pills (taken daily with a gradual dose reduction).\n\nParticipants will:\n\n* Receive either the study drug injection or prednisone pills for 24 weeks\n* Visit the clinic for checkups and lung function tests at weeks 6, 12, and 24\n* Have chest CT scans and blood tests to monitor their condition and any side effects\n* Be followed up for additional 24 weeks (up to week 48) to see if the disease comes back after treatment stops",[28],"Sarcoidosis, Pulmonary","NOT_YET_RECRUITING","2026-06-21",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":21},"2026-07",{"date":37,"type":21},"2028-07",{"name":39,"class":40},"Peking Union Medical College Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100496577","phase-1-feasibility-of-semaglutide-in-advanced-lung-disease-100496577","NCT05746039","Feasibility of Semaglutide in Advanced Lung Disease","Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study","Inclusion Criteria:\n\n* Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension\n* Age \\> 18\n* BMI \\> 30 kg\u002Fm2\n* Requires supplemental oxygen on exertion\n* Stable treatment regimen X 90 days\n* Use of disease-modifying therapy\n\nExclusion Criteria:\n\n* Diabetes\n* Pregnant or Breastfeeding\n* Recent weight loss\n* Recent or chronic GI complaints\n* History of gastroparesis\n* History of scleroderma\n* Hospitalized at time of evaluation\n* Use of weight loss medication in last 90 days\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)\n* Uncontrolled thyroid disease\n* History of acute\u002Fchronic pancreatitis\n* Prior suicide attempt\n* Suicidal ideation in last 90 days\n* Presence of a pacemaker or defibrillator","80 Years",{"count":51,"type":21},8,[53,24],"PHASE1","The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.\n\nThe main question\\[s\\] it aims to answer are:\n\n1. Are patients with advanced lung disease able to tolerate semaglutide therapy?\n2. Are we able to titrate semaglutide therapy to a target weight?\n\nParticipants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.",[56,57,58,28,59],"Obesity","Interstitial Lung Disease","Chronic Obstructive Pulmonary Disease","Pulmonary Hypertension",[61],"semaglutide","RECRUITING","2026-04-16",{"date":65,"type":33},"2026-04-21",{"date":67,"type":33},"2024-01-29",{"date":69,"type":21},"2027-12-28",{"name":71,"class":40},"University of Pennsylvania",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100611922","diagnostic-value-of-ebus-guided-transbronchial-mediastinal-cryobiopsy-versus-conventional-bronchoscopic-approaches-for-stage-iii-sarcoidosis-100611922","NCT07246876","Diagnostic Value of EBUS-Guided Transbronchial Mediastinal Cryobiopsy Versus Conventional Bronchoscopic Approaches for Stage I\u002FII Sarcoidosis","Inclusion Criteria:\n\n1. Age ≥18years;\n2. Patients with clinical and radiological suspicion of stage I or stage II sarcoidosis;\n3. Fully informed of the purpose and method of the study\n\nExclusion Criteria:\n\n1. Pathologically confirmed sarcoidosis, obvious organ involvement with the possibility of confirming granulomas using a minimally invasive diagnostic procedure;\n2. Patients with medical contraindications to bronchoscopy procedures.",{"count":79,"type":21},469,[81],"NA","Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), combined with endobronchial biopsy (EBB) and\u002For transbronchial lung biopsy (TBLB), and endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) have high diagnostic yields for patients with sarcoidosis. However, a direct comparison between them has not been conducted. This randomized controlled trial aims to compare directly the diagnostic yield between EBUS-TBMC and EBUS-TBNA+EBB+TBLB in sarcoidosis.",[28],[85,86,87,88],"Endobronchial Ultrasound","EBUS-TBNA","EBUS-transbronchial mediastinal cryobiopsy","Sarcoidosis","2026-02-04",{"date":91,"type":33},"2026-02-06",{"date":93,"type":21},"2026-03-01",{"date":95,"type":21},"2026-12",{"name":97,"class":40},"China-Japan Friendship Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100482830","risk-indicators-of-sarcoidosis-evolution-unified-protocol-100482830","NCT05567133","Risk Indicators of Sarcoidosis Evolution-Unified Protocol","Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis","RISE-UP","Inclusion Criteria:\n\n1. Adults with a diagnosis of sarcoidosis over the age of 18\n2. Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization\u002Fchronic beryllium disease, mycobacterial, viral, and\u002For fungal infection\n\nExclusion Criteria:\n\n1. Inability to tolerate study procedures as determined by the investigator\n2. Pregnant or breastfeeding\n3. Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases\n4. Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis\n5. Hematocrit (Packed Cell Volume) \\\u003C 25%","19 Years",{"count":108,"type":21},200,"OBSERVATIONAL","The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.",[28],[113],"sarcoid, lung, immune","2026-01-06",{"date":116,"type":33},"2026-01-08",{"date":118,"type":33},"2023-01-10",{"date":120,"type":21},"2030-03-30",{"name":122,"class":40},"University of California, San Francisco",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100503937","phase-4-hydroxychloroquine-as-a-steroid-sparing-agent-in-extrapulmonary-sarcoidosis-100503937","NCT05841758","Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis","Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized Trial","CAESAR","* Inclusion Criteria :\n\n  * at least 18 years of age\n  * pathologically proven sarcoidosis as defined by the American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS)\u002FWorld Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) criteria\n  * non severe ocular sarcoidosis requiring systemic treatment\n  * non severe skin sarcoidosis requiring systemic treatment\n  * non severe osseous sarcoidosis requiring systemic treatment\n  * non severe sarcoidosis with joint involvement requiring systemic treatment\n  * non severe sarcoidosis-related hypercalcemia requiring systemic treatment\n  * non severe peripheral nervous system sarcoidosis requiring systemic treatment\n  * non severe sarcoidosis-related non-severe Ear, Nose and Throat (ENT) involvement requiring systemic treatment\n  * symptomatic hypercalciuria \\>200 mg\u002F24h (24 h urine) OR\n\n    * \\- \\> 20 mg\u002Fmmol creatinine on urine sample\n    * \\- \\> 180 mg\u002Fg creatinine on urine sample\n  * signed informed consent\n  * affiliated to National French social security system\n* Exclusion Criteria :\n\n  * severe sarcoidosis involvement requiring another immunosuppressant or anti-TNF antibody or methylprednisolone i.v. pulses\n  * previous (\\\u003C3 months before screening) or concurrent treatment with immunosuppressants\n  * previous treatment with corticoid (patient weaned for 3 months before inclusion)\n  * previous treatment with antimalarial drugs (HCQ\u002FCQ) (patient must have been off plaquenil for at least 12 months)\n  * treatment with citalopram, escitalopram, hydroxyzin, domperidone and piperaquine\n  * known hypersensitivity or intolerance to HCQ\u002FCQ or 4-aminoquinoline derivatives and prednisone\n  * heart rhythm disorders on EKG (QT prolongation) (except atrial fibrillations)\n  * severe ophthalmological impairment or ophthalmological impairment that does not allow ophthalmic monitoring; previous history of maculopathy or retinopathy\n  * end-stage lung, liver, cardiac, or renal disease\n  * sarcoidosis with central nervous system involvement\n  * cardiac sarcoidosis\n  * clinical evidence of active infection (including infection with herpes virus and varicella-zoster virus) or severe\u002Funstabilized comorbidity (e.g. moderate to severe heart failure) or unstabilized psychosis\n  * chronic viral (HIV or HBV) infection\n  * untreated latent\u002Factive tuberculosis\n  * pregnancy or lactation (βHCG will be test by blood analysis at inclusion)\n  * concurrent vaccination with live vaccines during therapy\n  * inability to understand information about the protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study\n  * patient participating in other interventional research\n  * persons under court protection\n  * Use of effective contraception for the duration of the study . (Contraception is considered effective when it consists of one of the following: use of a male condom during all sexual activity and\u002For efficient oral hormonal contraception (better considered combined contraception) and\u002For an intrauterine device (IUD) and\u002For hormone-releasing intrauterine system (IUS) and\u002For history of bilateral tubal ligation and\u002For history of vasectomy, provided the male partner is the trial participant's only sexual partner and\u002For sexual abstinence)",{"count":133,"type":21},140,[135],"PHASE4","Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64\u002F100000; prevalence, 1-36\u002F100000\u002Fyear). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis.\n\nWhen indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series\u002Freports have shown CQ\u002FHCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ\u002FHCQ are daily used for skin, bone, and joint sarcoidosis, as well as hypercalcemia. Nowadays, HCQ is preferred over CQ because of a lower incidence of gastrointestinal and ocular adverse reactions, which can be minimized by close attention to the dosage and regular retinal examination. Its profile of safety is well-known since it has long been employed to treat systemic lupus erythematous or rheumatoid arthritis. Its action is thought to rely on its ability to accumulate in lysosomes of phagocytic cells, to affect antigen presentation and reduce pro-inflammatory cytokines. The investigator hypothesize that HCQ may be an efficacious add-on therapy for extra-pulmonary sarcoidosis leading to a significant steroid-sparing effect.",[28],[88,139,140,141],"Hydroxychloroquine","steroid-sparing agent","Extra pulmonary sarcoidosis","2025-09-09",{"date":144,"type":33},"2025-09-15",{"date":146,"type":33},"2024-07-30",{"date":148,"type":21},"2029-07-01",{"name":150,"class":40},"Hospices Civils de Lyon",21,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100552939","phase-4-rct-of-nintedanib-in-fibrotic-sarcoidosis-100552939","NCT06479603","RCT of Nintedanib in Fibrotic Sarcoidosis","A Randomised Controlled Trial to Study the Efficacy and Safety of Nintedanib in Fibrotic Sarcoidosis","NINSARC","Inclusion Criteria:\n\n* Age more than 18 years\n* Diagnosed with pulmonary sarcoidosis (clinico-radiologic presentation consistent with pulmonary sarcoidosis (with or without extrapulmonary involvement) along with presence of non-necrotising granulomatous inflammation in any of the involved organ\u002Ftissue and exclusion of a known cause for the granulomatous inflammation OR in the absence of demonstration of granulomatous inflammation in tissues, a diagnosis of fibrotic pulmonary sarcoidosis on a multidisciplinary discussion (enrolment of subjects meeting the latter criteria will be capped at 20% of the planned sample size)\n* Presence of signs of fibrosis on a computed tomography scan such as coarse reticulation, irregular lines, traction bronchiectasis, fibrotic masses, or honeycombing involving ≥20% of the lung fields on visual examination\n* Having symptoms of breathlessness grade 1 or more on the modified Medical Research Council (mMRC) scale or persistent cough for more than 3 months\n* Forced vital capacity (FVC) \\<80% predicted value for the age and sex of the subject using the reference equations for our subjects OR an exertional desaturation of 4% or more on a six-minute walk test (6MWT)\n* Receiving stable immunomodulatory treatment which includes standard of care drugs such as glucocorticoids alone or in combination with methotrexate, azathioprine, or mycophenolate mofetil for more than 3 months in a stable dose\n\nExclusion Criteria:\n\n* Known cardiopulmonary or other comorbid illness that can explain the subject's illness except group 3 pulmonary hypertension due to fibrotic pulmonary sarcoidosis\n* Hypersensitivity or contraindication to nintedanib (including high dose antiplatelets or anticoagulants, and bleeding diatheses)\n* Received an antifibrotic drug such as pirfenidone or nintedanib for ≥8 weeks in the past one year\n* Baseline deranged liver function (alanine aminotransferase and aspartate aminotransferase or bilirubin more than 1·5 times the upper normal limit \\[except in the case of Gilbert's syndrome\\])\n* Serum creatinine higher than 2.0 mg\u002FdL\n* Uncontrolled congestive heart failure\n* Other serious concomitant medical illness (eg, cancer), chronic debilitating illness (other than chronic HP), or drug abuse\n* Pregnancy (documented by urine pregnancy test) or breastfeeding\n* Unwilling to participate in the study",{"count":161,"type":21},120,[135],"Sarcoidosis is generally managed with outdoor immune modulatory drugs, most commonly oral steroids and at times drugs like methotrexate or azathioprine as a steroid sparing agent.\n\nAround 15-20% of sarcoidosis patient develop fibrosis of the lung parenchyma. The effect of antifibrotics in such patients needs more studies. Nintedanib has been used with good results in patients with fibrosing interstitial lung disease like IPF, SSC- ILD, and other progressive fibrosing ILD. By using nintedanib in fibrotic sarcoidosis it may be possible to limit the functional disability in these patients by slowing the rate of fibrosis and loss of lung function. The use of nintedanib if results in decrease in fibrosis and consequent decline in loss of lung function then it may be a safe and viable option for such patients.\n\nThe hypothesis of this study is that in patients with fibrotic sarcoidosis on standard of care anti-inflammatory therapy, nintedanib may help in reducing the rate of decline in lung function and progressive fibrosis. The aim is to evaluate the efficacy and safety of nintedanib in subjects with fibrotic sarcoidosis",[28],"2024-10-21",{"date":167,"type":33},"2024-10-23",{"date":169,"type":33},"2024-06-30",{"date":171,"type":21},"2026-01-31",{"name":173,"class":40},"Post Graduate Institute of Medical Education and Research, Chandigarh"]